Insulet (NASDAQ: PODD) reported Q4 EPS of $0.16, $0.09 better than the analyst estimate of $0.07. Revenue for the quarter came in at $164.8 million versus the consensus estimate of $162.46 million.

• Fourth quarter 2018 revenue of $164.9 million, up 26% compared to $130.5 million in the prior year, exceeds guidance of $159 to $164 million
  • U.S. Omnipod revenue of $93.2 million, an increase of 22%
    • International Omnipod revenue of $55.0 million, an increase of 54%
    • Drug Delivery revenue of $16.7 million, a decrease of 8%
• Gross margin of 66.9%, up 600 basis points
• Operating income of $16.2 million compared to an operating loss of $0.8 million in the prior year
• Net income of $9.9 million, $0.16 per diluted share, compared to a net loss of $6.9 million, $(0.12) per share

"Insulet had a remarkable 2018, achieving our third consecutive year of over 20% revenue growth, significantly improving gross margin, and achieving profitability for the first year in the Company\'s history," said Shacey Petrovic, President and Chief Executive Officer. "Our fourth quarter and full year results were driven by strong commercial and operational execution and gives us great momentum, ensuring more people with diabetes can benefit from our life-changing technology."

Ms. Petrovic continued, "Insulet has multiple value creation catalysts ahead and we are well on our way to achieving our 2021 financial targets of $1 billion in revenue, 70% gross margin and mid-teens operating margin. We have ambitious plans for Insulet and we are confident we will continue our strong growth trajectory and create value for shareholders."

GUIDANCE:

Insulet sees Q1 2019 revenue of $152-156 million, versus the consensus of $155.94 million.

Insulet sees FY2019 revenue of $662-687 million, versus the consensus of $691.74 million.

For earnings history and earnings-related data on Insulet (PODD) click here.